Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

69.85USD
17 Aug 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$69.85
Open
--
Day's High
--
Day's Low
--
Volume
3
Avg. Vol
5,432,760
52-wk High
$75.04
52-wk Low
$55.06

ABBV.K

Chart for ABBV.K

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $111,347.50
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 3.66

Financials

  ABBV.K Industry Sector
P/E (TTM): 17.06 31.64 32.84
EPS (TTM): 4.09 -- --
ROI: 11.74 15.30 14.86
ROE: 113.57 16.32 16.11

BRIEF-Abbvie's Maviret approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes

* Abbvie's Maviret approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes Source text for Eikon: Further company coverage:

Aug 17 2017

FDA approves AbbVie's hepatitis C drug

The U.S. Food and Drug Administration on Thursday approved AbbVie Inc's drug to treat certain adults with chronic hepatitis C.

Aug 03 2017

BRIEF-U.S. FDA says approved Abbvie's Mavyret for Hepatitis C

* U.S. FDA- FDA granted the application priority review, breakthrough therapy designations, granted approval of Mavyret to Abbvie Inc ‍​ Source text : (http://bit.ly/2vxrKo3) Further company coverage:

Aug 03 2017

Fitch Downgrades AstraZeneca to 'A-'; Outlook Negative

(The following statement was released by the rating agency) LONDON, August 01 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating to 'A-' from 'A'. The Outlook is Negative. The downgrade reflects AstraZeneca's increasing business risk as the pharmaceutical group transitions into next-generation therapies. The company's recent mixed late-stage pipeline developments in oncology - an increasing

Aug 01 2017

REFILE-BRIEF-AbbVie to delist from Euronext Paris

* This request has been approved by the Board of Directors of Euronext Paris SA

Jul 31 2017

AbbVie's drug for all types of hepatitis C wins EU approval

AbbVie Inc said on Friday it had received European approval to market its drug for treatment of all six major forms of hepatitis C.

Jul 28 2017

AbbVie's drug for all types of hepatitis C wins EU approval

July 28 AbbVie Inc said on Friday it had received European approval to market its drug for treatment of all six major forms of hepatitis C.

Jul 28 2017

BRIEF-EC grants Abbvie's Maviret marketing authorization for treatment of Chronic Hepatitis C

* European Commission grants Abbvie's Maviret (glecaprevir/pibrentasvir) marketing authorization for the treatment of Chronic Hepatitis C in all major genotypes (GT1-6)

Jul 28 2017

AbbVie to remain cautious on drug pricing, shares fall

AbbVie Inc's said it would be cautious with drug pricing, especially for Humira, the world's biggest selling drug, sending its shares down 2 percent, despite the drugmaker's quarterly profit narrowly beating estimates.

Jul 28 2017

UPDATE 3-AbbVie to remain cautious on drug pricing, shares fall

* Co reiterates 2017 adjusted profit forecast (Adds conference call details, shares)

Jul 28 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $133.04 -1.13
Pfizer Inc. (PFE.N) $32.95 -0.41
Novartis AG (NOVN.S) CHF80.00 -0.65
Merck & Co., Inc. (MRK.N) $61.81 -0.89
Roche Holding Ltd. (ROG.S) CHF242.40 -1.80
Roche Holding Ltd. (RO.S) CHF245.80 -1.00
Abbott Laboratories (ABT.N) $49.29 -0.52
Eli Lilly and Co (LLY.N) $77.80 -2.89
Sanofi SA (SASY.PA) €81.58 -1.18

Earnings vs. Estimates